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ABSTRACT
In  this  paper  we  have  used  western  blotting  to  study  the  phosphorylation  of  the  intracellular 
enzymes  ERK (MAPK) and Akt  as  well  as  the  EGF receptor  in  response  to  stimulation  with  
neurotensin  (NT) and epidermal  growth factor  (EGF).  Both these substances  activate  signaling 
cascades frequently overactive in cancer. Cells from the Panc-1 cell line, which is derived from a 
human ductal  pancreatic  carcinoma,  have  been used in  our  experiments.  Previous  studies  have 
investigated ERK activation in these cells, but little is reported about Akt (PKB) phosphorylation in 
response to NT stimulation. We wanted to see whether or not NT induced transactivation of the 
EGF receptor and we also studied the effect of preincubation with different inhibitors in order to 
elucidate  by  which  mechanisms  EGF-  and  NT-induced  phosphorylation  occur.  Finally,  we 
stimulated our cells  with thapsigargin or tetradecanoyl  phorbol acetate  (TPA) to investigate  the 
effect of increased intracellular calcium and activation of protein kinase C (PKC), respectively. 
Results: EGF and NT stimulated ERK- and Akt-phosphorylation in a dose dependent fashion. EGF 
also  stimulated  EGFR  phosphorylation  dose  dependently.  We  detected  no  NT-induced 
transactivation of EGFR. NT- and EGF-induced Akt activation was not mediated through PKC or 
increased intracellular calcium. NT-induced ERK activation seemed to be PKC-dependent, whereas 
EGF- induced ERK activation was reduced by 50% when inhibiting PKC.
INTRODUCTION
Background
Pancreatic cancer, of which 90% are ductal adenocarcinomas, has a 5 year survival rate of 5% when 
all stages are included [1][2]. This, together with its estimated incidence of about 36.000 new cases 
pr year in the US only, makes it the fourth leading cause of cancer death in both men and women 
[2]. With these grave statistics at hand, the hope is that novel therapeutic strategies can arise from a  
better understanding of the signaling pathways that stimulate the lethal proliferation and migration 
of ductal pancreatic cancer cells [1][3]. Unfortunately, the last 20 years of research in the field has 
not contributed to any significant improvement in clinical treatment or early detection of pancreatic 
cancer,  although the knowledge of  cellular  mechanisms present  in  this  cancer  undoubtedly has 
increased  [2][4] . 
Receptor tyrosine kinases
Receptor tyrosine kinases (RTKs) are transmembrane glycoproteins with a cytoplasmatic domain 
that  harbors  tyrosine  kinase  activity.  Binding  of  appropriate  ligands,  such  as  EGF,  in  the 
extracellular domain allows EGFR dimerization, which induces cross-phosphorylation and thereby 
activation.  Activated RTKs recruit  different protein complexes to the membrane which initiates 
different signaling cascades. Three of these will briefly be mentioned (Fig. 1): 
Recruited  phosphoinositide  3-kinase  (PI3K)  phosphorylates  phosphatidylinositol-(4,5)-
bisphosphate (PIP2) producing phosphatidylinositol-(3,4,5)-trisphosphate (PIP3). The available PIP3 
acts  as  a  binding  site  for  Akt,  which  upon  binding  reveals  its  two  amino  residues  for 
phosphorylation. Once phosphorylated, Akt acts as a kinase for many downstream proteins and is 
thereby involved in regulating protein synthesis, cell survival, proliferation and metabolism.[5][6]. 
A major regulator of this signaling pathway is PTEN, a phosphatase that reduces the available PIP3 
by  converting  it  back  to  PIP2.  Not  surprisingly,  loss  of  PTEN  function  contributes  to  cancer 
development [6]. 
The Ras/Raf/MEK/ERK pathway is another downstream pathway of RTK  activation. Activated 
RTKs recruit the Grb2-son of sevenless (SOS) complex, which loads membrane bound Ras with 
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GTP and thereby activates it. Activated Ras-GTP then recruits Raf to the membrane, which in turn 
activates mitogen activated protein kinase-1 (MEK-1). MEK1 phosphorylates ERK-1 and ERK-2 at 
specific  sites,  thus  activating  them.  Activated  ERK has  numerous  targets  and  is  an  important 
regulator of cell growth [5][7]. 
Phosphorylated RTKs can also activate phospholipase C-γ (PLC-γ) and thereby induce formation of 
inositol-(1,4,5)-trisphosphate (IP3) and diacylglyserol (DAG) from PIP2. These second messengers 
initiate  further  signaling  by  mobilizing  intracellular  calcium  and  activating  protein  kinase  C, 
respectively [8]. 
Targeting of signaling pathways in the treatment of cancer has been met with some success. These 
treatments have primarily targeted RTKs such as the EGFR in the case of lung cancer bearing 
mutations and/or amplification of the EGF receptor  [5][6]. In 2005 the FDA approved the EGFR 
inhibitor erlotinib in combination with gemcitabine in the treatment of pancreatic cancer. However, 
what was gained  was only an increase from 17% to 23% in the 1 year survival [9]. In some cases 
RTK inhibitors  do  not  work,  or  perhaps  even  more  frustrating,  the  cancers  develop  resistance 
against these drugs, for instance by secondary mutations [5]. This raises the demand for drugs that 
intervene at other steps in the signaling cascade that is initiated by RTKs. The PI3K-Akt signaling 
pathway has been found to be inappropriately activated in many cancers, and the two most frequent 
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Figure 1. This chart shows the signaling pathways activated by NT and EGF (here replaced by a  
general  growthfactor,  GF)  mentioned  in  the  text.  Signaling  downstream  of  ERK  and  Akt  has  
therefore been left out. Note that RTKs can activate ERK by signaling through both Ras and PLC.  
Non-physiologic substances added in some of our experiments are shown in light colors. LP, Ligand  
precursor  (for  GFs);  MMPs,  matrix  metalloproteinases;  Cet,  cetuximab;  Gef,  gefitinib;  Thaps,  
thapsigargin, TPA, tetradecanoyl phorbol acetate; GF-X, GF-109203 X. This chart is simplified,  
see text and other relevant literature for other abbreviations and further details.
reasons for this is in fact RTK activation and somatic mutations in specific components of this 
signaling pathway [5][6]. It has even been demonstrated that for a RTK inhibitor to be effective in 
treatment,  it  must  down-regulate  PI3K  signaling  [6].  This  has  spurred   the  development  of 
numerous drugs targeting components of the PI3K pathway. As for our Panc-1 cells, these cells 
have been shown to harbour elevated expression of Akt2 and KRas [10]. The former is a part of the 
PI3K signaling pathway, and a promoter of cellular invasiveness and mesenchymal characteristics, 
whereas  the  latter  is  part  of  the  important  Ras/Raf/MEK/ERK  pathway  shown  to  promote 
proliferation and avoidance of apoptosis when activated  [5][6][11]. Activated KRas is among the 
most common genetic alterations in pancreatic cancer, but all attempts to directly block mutated 
KRas function have failed so far  [4][12].  The mutated KRas does not  seem to be sufficient  to 
promote constitutive activation of the ERK pathway in Panc-1 cells, although there seems to be 
some disagreement concerning this [3][13].
Epidermal Growth Factor
EGF is a 6 kDa protein discovered in 1960. It is a signaling molecule that stimulates the growth of  
epithelial  tissues during development  and throughout  life. Among many other  human epithelial 
cancers, pancreatic cancer cells have been reported to overexpress certain members of the EGFR 
family, and even secrete EGFR ligands including TGF-ɑ and EGF itself  [1][13]. This implies that 
there might be an autocrine loop of selfstimulation causing and maintaining a malignant phenotype 
[1]. Indeed, one study found a direct linear correlation between sensitivity to an EGF inhibitor 
(gefitinib) and TGF-ɑ production when looking at 9 different human pancreatic cancer cell lines 
[13].
G protein-coupled receptors
G protein-coupled receptors (GPCRs) are structurally characterised by their 7 transmembrane alpha 
helices. They relay a wide range of signals from a large number of agonists, and these receptors are 
in  fact  the  largest  group of  cell  surface  proteins  involved in  signal  transduction  [14][15].  This 
position in physiology has made GCPRs the target of more than half of all currently available drugs 
[15]. Heterotrimeric G proteins consist of  α, β and γ subunits.  Upon binding of an extracellular 
agonist, the GPCRs α-helices move, causing a conformational change in the cytoplasmatic domain 
of the receptor. This leads to the exchange of GDP for GTP in the α subunit of the G protein. This 
exchange  causes  conformational  changes  in  the  G protein,  activating  the  Gα-GTP subunit  and 
revealing effector interaction sites in the βγ heterodimer. These activated subunits can then relay 
signals in different ways. Inactivation happens partially by GTP hydrolysis by the Gα subunit and 
partially  by  acute  homologus  desensitization  initiated  by  GPCR  kinases  (GRKs)  [14][15].  G 
proteins are classified into four groups according to their specific α subunit: G s, Gi Gq and G12 [14] 
[15]. In general, the Gq family controls the activity of phosphatidylinositol-specific phospholipases 
such as phospholipase C-β (PLC-β), whereas the PLC-γ is regulated by tyrosine kinases, although 
there probably is some overlap [8]. Activated PLC catalyzes the hydrolysis of PIP2 to produce the 
two second messengers  IP3 and DAG which, as previously mentioned, mobilize intracellular Ca2+ 
and protein kinase C (PKC) respectively (Fig. 1) [3]. NT is one of many GPCR agonists capable of 
activating Gq in this manner [16]. 
Transactivation
An important signaling pathway present in many cells is GPCR-induced phosphorylation of the 
EGFR receptor (transactivation), which causes Ras-dependent ERK activation [14]. In many cases 
this transactivation is mediated by the release of ligand precursors mediated by metalloproteinases 
that are activated by GPCRs [14]. This was also demonstrated in Panc-1 cells where it also turned 
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out that transactivation is strongly inhibited by PKC, thereby explaining earlier failed attempts to 
provide evidence of this mechanism (Fig. 1) [3][17].  
Neurotensin
NT, a 13 amino acid peptide discovered in 1973, acts as a neurotransmitter in the central nervous 
system and as an endocrine agent in the periphery, being especially abundant in the gastrointestinal 
tract [18]. NT acts through binding to GPCRs which activate PKC [3]. PKC can then activate ERK 
through the Ras/Raf/MEK/ERK pathway, although there also seems to exist PKC-independent ERK 
activation pathways depending on cellular context [14]. Although NT has numerous physiological 
effects  on multiple organs,  one major reason for its  attention in the scientific community is its 
ability to act as a potent cellular mitogen for multiple cell types [1][14][18]. Even more interesting 
is the frequent expression of NT and its receptor in malignant cells. Autoradiography of frozen 
sections of human pancreatic  cancer  specimens revealed NT binding sites  in about  75% of the 
cases, compared to no NT receptors in chronic pancreatitis or normal pancreatic tissue  [1]. This 
study included pancreatic acini, ducts and islets.  Another study, using immunohistochemistry to 
look at pancreatic duct specimens only, reported similar figures. In this case 80% of the cancer 
specimens expressed both NT and its receptor, compared to 20% with weak expression of NT and 
no expression of the receptor in the controls  [19]. It has also been shown that the expression of 
mRNA for  the  NT receptor  subtype  1  is  markedly increased  in  ductal  pancreatic  cancer  cells 
compared  to  normal  controls  [1].  Finally,  it  has  been  found  that  neuroendocrine  cells  in 
intrapancreatic ganglia in both malignant and healthy tissue can produce NT and thus stimulate the 
overabundant  NT  receptors  present  in  ductal  pancreatic  cancer  cells  [1].  Considering  these 
differences between normal and malignant tissue, the potential value of knowing the NT signaling 
mechanisms becomes obvious in future attempts to design new drugs against pancreatic cancer. 
CHEMICALS
Dulbecco’s modified Eagle’s medium, penicillin and streptomycin were from Gibco (Grand Island, 
NY).  Neurotensin,  12-O-tetradecanoylphorbol-13-acetate  (TPA),  thapsigargin,  epidermal  growth 
factor (EGF) and Ponceu S solution were obtained from Sigma-Aldrich (St.Louis, MO). [2-[1-(3-
dimetylaminopropyl)-1H-indol-3-yl]-maleimide] (GF109203X))  was purchased  from Calbiochem 
(San  Diego,  CA).  4-Quinazolinamine,  N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-
morpholin)propoxy]  (gefitinib)  was  a  gift  from  Astra  Zeneca  (LondonCheshire,  UK),  and 
cetuximab  was  kindly  provided  by  Merck  KgaA  (Darmstadt,  Germany).  Antibodies  against 
phosphorylated  Akt  (Ser473),  dually  phosphorylated  ERK  (Thr202/Tyr204)  and  phospho-EGF 
receptor  (Tyr1173)  were  obtained  from  Cell  Signaling  Technology  (Boston,  MA).  Anti-ERK 
antibodies was obtained from Upstate (Billerica, MA). Secondary antibodies were purchased from 
Bio-Rad  Laboratories  (Hercules,  CA).  All  other  chemicals  were  of  analytical  quality.  Stock 
solutions of test compounds were prepared in DMSO (TPA, thapsigargin, gefitinib) or 0.9 % NaCl 
(neurotensin,  GF109203X  ).  EGF  was  dissolved  in  4  mM  HCl.  Cetuximab  was  dissolved  in 
phosphate-buffered  saline  (PBS).  When  solutions  containing  DMSO  were  used,  the  final 
concentration of DMSO was kept as low as possible.
CELL CULTURE
Pancreatic adenocarcinoma cell line Panc-1 was obtained from ATCC (Manassas, VA). The cells 
were maintained in Dulbecco’s modified Eagle’s medium containing 4.5 g/l glucose supplemented 
with  10  %  fetal  bovine  serum,  penicillin  (67  μg/ml),  streptomycin  (100  μg/ml)  and  4  mM 
glutamine. Cells were plated onto Costar plastic culture wells (Corning Life Sciences, Acton, MA) 
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at a density of 25 000 cells/cm2. The cultures were kept in 95% air/5% CO2 at 37°C. After 24 hours 
the medium was replaced with serum-free medium and the cells were cultured for another 24 hours 
before  stimulation  with  agonists.  Cells  were  stimulated  with  agonists  for  5  minutes,  unless 
otherwise stated. For stimulation,  the EGF concentrations ranged from 5 to 10 nM and the NT 
concentrations ranged from 100 to 1000 nM, unless otherwise stated. When inhibitors were present, 
these were added 30 minutes before agonist stimulation. The medium was then discarded, the cell 
layer was washed with 0.9% NaCl, and Laemmli buffer was added. The cells were scraped off with 
a cell lifter and transferred to Eppendorff tubes. Samples were boiled for 10 minutes. 
IMMUNOBLOTTING
Aliquots with ~15 000 cells (total cell lysate prepared in Laemmli buffer as described above) were 
electrophoresed on 10 % (w/v) polyacrylamide gels. This was followed by protein electrotransfer to 
nitrocellulose membranes. The membranes were stained with Ponceu S solution in order to evaluate 
protein transfer and guide the cutting of the membrane into three separate parts. These parts were 
then  rinsed  with  water  and  incubated  for  1  hour  in  a  dry  milk  blocking  solution  before 
immunoblotting  with  antibodies  against  phospho-Akt,  phospho-ERK1/2  and  phospho-EGFR. 
Immunoreactive bands were visualized with enhanced chemiluminescence using LumiGLO (KPL 
Protein Research Products, Gaithersburg, MD). Membranes were then stripped by placing them for 
5 minutes in 0,5 M NaOH. After rinsing them thoroughly with water, blocking, immunoblotting 
and  visualization  were  repeated,  using  antibodies  against  total  ERK  or  GAPDH  in  the 
immunoblotting process.
QUANTATION
Chemiluminescence was detected using a CCD camera (SensiCam) from Ultra-Violet Products. The 
dynamic range was set using in-house software (LabWorks version 4.6.00.0), images copied into a 
Microsoft word 97-2003 file, and then copied into ImageJ version 1.42q. Quantitation of the bands 
was made using a fixed width sampling tool. No background-correction was made in ImageJ, as it  
has been reported to worsen the results [20]. All densitometry results were obtained from analyzing 
the integral intensity of the middle third of the band, unless otherwise stated. When using LabWorks 
for quantitation we measured IOD with a fixed lane width as well. In our dose response experiments 
we  arbitrarily  set  100% intensity  (or  max  signal)  as  the  intensity  from the  bands  of  samples 
stimulated  with  the  highest  NT  or  EGF  concentration.  For  the  inhibition  of  EGF-induced 
phosphorylation by gefitinib, 100% is set as the intensity recorded without adding gefitinib. All 
error bars and uncertainties are presented as ±1 standard deviation.
RESULTS
Epidermal growth factor (EGF)
It has previously been shown that treatment of Panc-1 cells with EGF stimulates phosphorylation of 
EGFR,  Akt  and  ERK  [1][13].  Our  observations  support  this,  in  line  with  the  well  defined 
Ras/Raf/MEK/ERK and PI3K signaling known to be induced by receptor tyrosine kinases [1]. Our 
results  give EC50 estimates of 1.3 nM and 1.1 nM for pAkt and pERK respectively.  A typical 
western  blot  shown  below  illustrates  how  increasing  doses  of  EGF  result  in  increasing 
phosphorylation of EGFR, Akt and ERK (Fig 2). Using densitometry on repeated experiments we 
obtained the dose relationship presented in Figure 3. Since it has been reported that the width of the 
lane sample tool may affect the quantitative results, we did densitometry with both 100% and 30% 
lane width in our initial experiments [20]. This did not seem to make a substantial difference in our 
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results, as can be seen from the bottom left figure below (Fig. 3). “All” and “Center” refer to using 
100% and 30% width of the lane when sampling integrated intensities, respectively. Since Ponceu 
staining indicated some difference in transfer across the membrane, we tried to correct for this by 
using the total  ERK as a protein loading/transfer control and adjust the other signal intensities 
accordingly. We calculated correction factors by dividing the average of the total ERK intensity 
from all the lanes by the total ERK intensity of the specific lane. The corrected value was then 
obtained by multiplying the Akt, ERK or EGFR intensity by this correction factor. The effect of 
such corrections were small, comparing the results at the bottom left figure below (Fig. 3). It did 
however decrease the standard deviations slightly (numbers not presented) and this correction is 
used in the all dose-response figures presented, unless otherwise stated. Considering the possibility 
that previous detection with pERK antibodies and subsequent stripping might interfere with the 
total  ERK signal,  we plotted our correction factors against  pERK signal.  This test  provided no 
evidence of such interactions as the distribution looks fairly random as the pERK values increase 
(Fig. 3, bottom right). We also tested the effect of using GAPDH as a loading/transfer control to 
confirm that this uneven protein amount was not due to antibody interactions after stripping or an 
effect of the systematic application of samples in our dose response experiments (Fig. 4). As a final 
test of the quantitation method we compared the in-house LabWorks software with ImageJ software 
(Fig. 3). Results were yet again similar, and all further quantitative results  were obtained using 
ImageJ.
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Figure 2. Cells were incubated for five minutes with increasing concentrations of EGF.  
The basal Akt and ERK phosphorylation is difficult to see in print, but the increasing  
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7Figure 3. Average relative intensities of pERK, pAkt and pEGFR after stimulation with different  
doses of EGF. At the middle right all results are shown in one graph without error bars for clarity.  
Different methods of quantitation gave slightly different results as shown at the bottom left. «NC»  
refers to not using total ERK as a loading control. «Center» and «All» means middle third and  
entire band was used for densitometry respectively. «LabWorks» is the results obtained when using  
the in-house LabWorks software. n=3 for all results in this figure. At the bottom right we show  
the correction factors calculated from total ERK plotted against pERK intensity. Error bars indicate  
±1 standard deviation.




















































































































8Figure 4. There seemed to be a slight difference in transfer efficiency across the membrane, with  
the center lanes getting better transfer. To the left we show the correction factors estimated in our  
EGF dose response curves using total ERK as a tool to estimate total protein amount, n=3 . To 
the right we show correction factors estimated from different blots using GAPDH instead of total  
ERK, n=6 .  These  blots  were  not  from  dose-response  experiments.  The  results  are  similar,  
making this effect unlikely to be due to antibody interactions after stripping or an effect of the  
systematically increasing EGF doses in  the case of the EGF dose response curves.  Error bars  
indicate ±1 standard deviation.
















































It has previously been shown that NT induces a rapid and dose-dependent ERK phosphorylation in 
Panc-1 cells  [21].  This activation was later shown to be PKC-dependent,  and not only did NT 
induce phosphorylation, but it also induced translocation of the enzyme to the nucleus  [3]. Our 
results  indicate  a  dose-dependent  ERK response with an estimated EC50 of 1.8 nM. A typical 
western  blot  is  shown below (Fig.  5).  Although the standard deviations  from the  densitometry 
indicate no significant difference from 5-1000 nM, there seems to be a steadily increasing response 
from 1-100 nM as illustrated in the averaged results (Fig. 6).  There was some variation in behavior 
reaching 100 nM,  the  peak at  10 nM in  the  presented  blot  was  not  typical.  Although not  as 
convincing as for ERK, Akt phosphorylation does seem to be dose-dependent as well, with a stable 
response in the range 10-1000 nM NT (Fig. 6). The estimated EC50 of 0.65 nM is  of questionable 
value  as  the  basal  phosphorylation  is  about  40% of  what  NT maximally induced.  We did  not 
observe any EGFR phosphorylation.
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Figure 6. NT seems to induce ERK and Akt phosphorylation in a dose-dependent fashion. Samples  
without added NT is arbitarily set at 0.01 nM for comparison to the basal activity. The data point at  
0.3 nM NT was obtained from one single experiment. Error bars indicate ±1 standard deviation,
n=4 .
Figure 5. Cells were incubated for five minutes with increasing concentrations of NT.  
NT stimulated ERK and Akt phosphorylation. No bands were identified for pEGFR and 
this  blot  is  therefore  not  shown.  The  ERK  phosphorylation  is  convincingly  dose  
dependent  whereas  the same can not  be said for  Akt.  This  blot  shows a somewhat  
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The effect of three different inhibiting substances were examined in our experiments, one PKC 
inhibitor, GF 109203X (from now on referred to as GF), and two EGFR antagonists cetuximab and 
gefitinib (gef) [22][23]. Cetuximab and gefitinib work by preventing ligand binding, and inhibiting 
the receptor tyrosine kinase by competitively replacing ATP, respectively [23]. GF inhibits PKC by 
competitively replacing ATP  [22]. All inhibitors were added 30 minutes before agonist stimulation.
Effect of inhibitors combined with EGF
Preincubation with 3.5 μM GF consistently reduced the EGF-induced ERK phosphorylation in our 
experiments (Fig. 7). The effect upon Akt and EGFR was somewhat less obvious. We calculated 
intensity ratios by dividing the band intensity from samples preincubated with GF (+GF) by the 
band intensity from samples not preincubated with GF (-GF). For pAkt the intensity ratio +GF/-GF 
was 1.3±0.5 whereas for  pERK the result was 0.5±0.1 . In other words, there was no reliable 
effect upon pAkt, but a marked attenuation of pERK. For EGFR the ratio was 1.0±0.8 . There 
seemed to be a small effect on basal pAkt on adding GF, but the results varied and quantitation 
revealed an insignificant +GF/-GF ratio for the controls of 1.6±0.8 .
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Figure 7. EGF-induced ERK phosphorylation was slightly inhibited by 30 minutes of  
preincubation  with  3.5  μM  GF.  Although  not  readily  visible  in  this  figure,  the  
quantitation of this blot actually gives an intensity ratio for +GF/-GF of 0.75 when not  
corrected for GAPDH, and 0.66 when corrected.  Akt phosphorylation seemed to be  
slightly increased, whereas no conclusion could be drawn from the EGFR blotts. Since  
EGF induces such strong Akt phosphorylation it was necessary to overexpose blotts  
where both EGF and NT effects were studied to see the effect of NT upon Akt. The two  
pAkt  blots  shown at  the bottom are in  fact  the same but  with different  amounts  of  
exposure.
      pERK
 NaCl     EGF             NT     NaCl       EGF                   NT
 NaCl GF 
        GAPDH
     pAkt
         pAkt(2)
Gefitinib (also known as  ZD1839 or  Iressa)  is  a  reversible  competitive inhibitor  of  the  EGFR 
tyrosine kinase ATP-binding site [24]. We observed inhibition of EGF-induced EGFR, Akt and ERK 
phosphorylation in a dose dependent manner as expected from other reported experiments (Fig. 8) 
[13]. Quantitative results of three experiments are shown in Figure 9.
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Figure 8.  Increasing doses of gefitinib (gef) inhibit the phosphorylation of EGFR, Akt  
and ERK. With closer inspection one might notice the increased phosphorylation of  
ERK at the highest dose of gefitinib.
   pERK
   ERK
   pAkt
       pEGFR
 NaCl gef, 10-7  gef, 10-6  gef, 10-5
EGF - - - - -+ + + + + + + + +
Figure 9. To the left: EGF-induced phosphorylation of EGFR, Akt and ERK is effectivly inhibited  
by gefitinib. The pAkt point at 1nM is hidden underneath the pERK point. 100% band width was  
used for quantitation. Error bars indicate ±1 standard deviation, n=3 . To the right, all the  
data from the experiments put in one figure for perspective.



































30 minutes of preincubation with 25 μg/mL cetuximab completely abrogated the EGF-induced 
phosphorylation of EGFR, Akt and ERK in the Panc-1 cells (Fig. 10). 
Effect of inhibitors combined with NT
Pretreatment with 3.5 μM GF almost nullified NT-induced ERK phosphorylation (Fig. 7). This was 
to be expected, as there already is convincing evidence that NT-induced ERK phosphorylation is 
strongly PKC-dependent in Panc-1 cells  [3]. GF had no major effect on Akt activation, although 
densitometry revealed a small difference with the intensity ratio for +GF/-GF being 0.93±0.03 .
Pretreatment with 10  μM gefitinib did not affect NT-induced ERK phosphorylation, whereas Akt 
phosphorylation seemed to be decreased to basal levels (Fig. 11).
Pretreatment with 25 μg/mL cetuximab insignificantly attenuated ERK phosphorylation, +Cet/-Cet 
ratio 0.8±0.2 , but did not affect Akt phosphorylation (Fig. 10). 
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Figure 10. Thirty minutes of preincubation with 25 μg/mL cetuximab abrogates EGF-
induced  ERK,  Akt  and  EGFR phosphorylation.  It  also  attenuates  NT-induced  ERK  
phosphorylation.
 NaCl EGF      NT NaCl EGF        NT





Figure 11. Pretreatment with 10  μM gefitinib for 30 minutes has no effect upon NT-
induced ERK phosphorylation but does reduce Akt phosphorylation to a basal level.  
Upon closer inspection one might notice the slightly increased ERK phosphorylation in  








Role of PKC and increased intracellular calcium
Tetradecanoyl phorbol acetate (TPA) is known to be a tumor promoter and an activator of PKC 
[25]. Paradoxically it has also been shown to inhibit cell proliferation in some cells including Panc-
1  cells [26][27][28]. Although one study failed to detect ERK phosphorylation in response to TPA 
stimulation, others have reported it to be present in both Panc-1 cells and another pancreatic cancer 
cell line CD18 [27][28]. Our results indicate that 1  μM TPA stimulated phosphorylation of ERK, 
but not Akt or EGFR (Fig. 12). The mechanism by which TPA inhibits cell proliferation has been 
related to changes in cyclin expression [28]. 
Thapsigargin (Thaps) is known to increase the cytoplasmatic calcium in Panc-1 cells partially by 
release  from intracellular  ER  stores  and  partially  by  inhibiting  intracellular  Ca2+-ATPases  that 
normally pump Ca2+ from the cytoplasm back into intracellular stores [29][30]. In our experiments 1 
μM thapsigargin had the same effects as TPA, i.e only ERK was phosphorylated, although to a 
slightly lesser extent at the concentrations used (Fig. 12). No literature was found concerning the 
effects  of  thapsigargin  in  Panc-1  cells,  but  one  study reported  ERK  activation  in  response  to 
thapsigargin in COS7 cells [31]. 
DISCUSSION
Methods
The many pitfalls of densitometry have been pointed out in a recent article [20]. We minimized our 
methodological  errors  by following the  recommendations  of  using  30% lane  width,  measuring 
integral intensity and doing no background correction with the rolling ball algorithm [20].  We also 
checked  that  at  least  two  different  softwares  provided  the  same  results  in  several  of  our 
measurements. This indicates, among other things, that the data transfer via a Word file did not  
introduce  any significant  error  which  one  might  suggest  if  left  untested.  To  further  assert  the 
robustness of our method we analyzed the same samples with two independent western blots when 
investigating  the  EGF dose  responses.  The  results  indicated  a  high  degree  of  precision  in  the 
analysis of the samples, with considerably larger variations between the samples themselves (results 
not shown). This being said, the accuracy of the results is more difficult to evaluate. A linearity 
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Figure 12. Five minutes of stimulation with  1  μM  TPA and  1  μM  thapsigargin both 
induce  ERK-  but  not  Akt-  or  EGFR-phosphorylation.  The  EGF-pAkt  bands  were  
overexposed to clearify that NT really activates Akt, which is somewhat unclear from  
the top pAkt exposure.
         NaCl    NT    EGF      DMSO    TPA     Thaps
 pERK
         ERK
   pAkt
       pAkt-120s
         pEGFR
     EGF
between chemiluminescence signal and amount of phosphorylation is  something that has  been 
assumed, but is not necessarily true. In determining the dose response curves the membranes were 
exposed once. It might have been better to expose for long enough time to get readily visible bands 
at the lowest concentrations, decrease the exposure time when studying the higher concentration 
and incrementally calculate intensity ratios. The attempted correction for total protein used in the 
dose-response  figures  might  be  claimed  improper  because  of  a  possible  interaction  between 
phospho-ERK  and  total-ERK  antibodies.  Such  an  interaction  could  produce  a  systematically 
decreased or increased total-ERK signal depending on the degree of phosphorylation of ERK, but 
this did not seem to be the case as illustrated by the distribution of points in the bottom right figure 
of Figure 3. Finally, we observed the same systematic trend of stronger chemiluminescence signals 
towards the middle of the blots when measuring GAPDH as we did when measuring total ERK 
(Fig. 4). The effect might stem from the transferring process as the Ponceu coloring indicated, or it 
might be caused by other effects such as the angle between the detector and the membrane, or the  
binding of antibodies.
In  our  intensity  ratio  calculations  we  compared  bands  in  which  the  samples  had  been  either 
preincubated with an inhibitor I (+I) or not preincubated with I (-I) before stimulation with NT or 
EGF, providing an intensity ratio +I/-I. This method does not take into account that the fact that I  
might have some effect on the intensity by itself and not only by modulating the EGF/NT effect.  
Such an effect would have been seen in the controls receiving I only, and where suspicion was 
raised we calculated intensity ratios for the control samples as well. The perhaps most obvious way 
of comparing intensities, dividing stimulated- by control-intensity, was not a viable option as the 
controls mostly gave weak signals, and the ratios were thus very sensitive to small changes. This 
was especially the case when analyzing pERK signals, and keeping it simple we applied the same 
method when analyzing pAkt signals. The times we did calculate intensity ratios for the controls the 
large standard deviations rendered the possible trend uninformative. Correction using GAPDH or 
total ERK did not affect these results considerably. We did however correct our values as our blots 
were not designed to evaluate quantitative differences. This meant that +I and -I lanes often were 
separated by some other lanes which could alter the results if not corrected (Fig. 4).
Dose response curves
Our results have shown that both EGF and NT can activate Akt and ERK in a dose-dependent 
manner. In the case of EGF stimulation, Akt and ERK responses were quite similar, while EGFR 
phosphorylation  required  higher  amounts  of  EGF  to  reach  the  same  degree  of  relative 
phosphorylation. This might be interpreted as a high sensitivity/quick response of ERK and Akt 
phosphorylation  in  response  to  the  upstream  EGFR  activation.  Although  a  study  measuring 
incorporation  of  [3H]-thymidine  into  DNA showed  a  plateau  in  incorporation  when  the  EGF 
concentration reached about 1 ng/mL, the phosphorylation shows a continuous increasing response 
up  to  10  ng/mL  [1].  This  indicates  that  at  maximal  stimulation  of  DNA synthesis  through 
ERK/Akt/EGFR  signaling,  there  is  still  a  quite  substantial  amount  of  unphosphorylated 
ERK/Akt/EGFR left. Since we did not seem to reach maximal phosphorylation of the EGFR in our  
EGF experiments we did not estimate an EC50 value in this case. For ERK the response to NT and 
EGF both gave strong increases in phosphorylation at concentrations of 10 nM for both substances. 
EGF was slightly more potent  with an EC50 of 1.1 nM compared to  1.8 nM for NT. For Akt 
however, the response to NT was much weaker than the response to EGF. The increase in signal 
when stimulated with maximal doses of NT was in fact only about twice the basal signal whereas 
the increase in signal when stimulated with maximal doses of EGF was about 20 times.  These 
figures do of course depend on the doses of NT and EGF used, but it does not look as if even further 
increased NT doses would give any increased response. At 0.5 nM EGF, the Akt phosphorylation is  
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similar to that of 1000 nM NT illustrating the difference in efficacy. The uncertainties in the NT-Akt 
response curve are large, probably due to the limitations of our method in discriminating between 
the  small  differences  present.  Earlier  studies  have  reported maximal  NT-induced  ERK 
phosphorylation in the range 5-100 nM whereas our results suggest a maximal response in the range 
10-100 nM [21]. It has been suggested that NT-mediated mitogenic signaling in pancreatic cancer 
cell lines is concentration-dependent with inhibition at high NT concentrations [32]. This does not 
however seem to be related to effects on ERK phosphorylation in Panc-1 cells in our or others  
results  [21].  Although evidence has suggested that PKCα-mediated inhibition of GPCR-induced 
EGFR transactivation may explain why NT did not induce EGFR phosphorylation, we were not 
able to detect any EGFR phosphorylation in NT stimulated cells pretreated with or without GF [17]. 
This might be due to methodological differences, as the previous study used immunoprecipitation, 
different antibodies and incubation with with GF for one hour. This is probably a more sensitive 
method as they reported a NT-induced reduction in basal EGFR phosphorylation, while we in our 
studies were not able to detect a basal EGFR phosphorylation. EGF stimulation phosphorlylated 
EGFR in a dose dependent manner.
Phosphorylation of ERK
The EGFR inhibitors gefitinib and cetuximab both abolished EGF-induced ERK phosphorylation at 
appropriate doses. The slight increased pERK signal observed when going from 1 μM to 10  μM 
gefitinib is most likely due to some nonspecific (physio-chemical) effect, and it should be noted that 
the intensity relative to the control intensity was basically 1, so at these concentrations there was in 
fact no effect of EGF on the ERK phosphorylation [24]. The observations when inhibiting the EGF 
receptor were to be expected as these inhibitors block upstream signaling, but we also observed that 
the PKC inhibitor GF decreased ERK phosphorylation to about 50% of the value without GF. This 
indicates  that  half  of  the EGF-induced ERK phosphorylation is  signaled through PKC and not 
through the  known EGFR/Ras/Raf/MEK/ERK pathway  [3]. Although  cell  context  is  critical  in 
studying transduction pathways,  it  has  been reported that  EGFR seems to signal  to  mTOR via 
PKCα in glioma cells, making such a mechanism plausible in Panc-1 cells as well  [14][33].  One 
study showed that preincubation with GF did not affect EGF-induced [3H]-thymidine incorporation 
[1]. Assuming that GF inhibits EGF-induced ERK phosphorylation by 50% and this corresponds to 
halving the EGF concentration for the sake of ERK phosphorylation one would indeed expect that 
they would find no significant difference since this means that [3H]-thymidine incorporation still is 
at  its  maximal  plateau  level  (going  from  2  ng/mL to  the  corresponding  1  ng/mL  with  GF 
preincubation in their experiments). Thus they provide little evidence to claim that EGF-induced 
ERK phosphorylation is independent of PKC since even our blots do not point in the direction of 
partial PKC dependence when inspected with the naked eye. Further studies are required to see if 
the effect of GF is present at other concentrations of EGF and GF. It had previously been shown that 
NT induces ERK phosphorylation (and c-Raf-1 stimulation) through a PKC-dependent pathway, 
which our results with NT-stimulated GF treated cells support [3]. Substantiating the central role of 
PKC in mediating ERK phosphorylation we showed that ERK could be phosphorylated by PKC 
directly by activating it using TPA. Thapsigargin also induced ERK phosphorylation, possibly by 
causing increased intracellular  Ca2+ levels,  which in  turn can activate  PKC, and/or  possibly by 
stimulating the Ras/Raf pathway via RasGRF [15]. These possible pathways could be investigated 
by  comparing  thapsigargin-stimulated  cells  that  were  preincubated  with  or  without  GF.  We 
conducted  one  such  preliminary  experiment  in  which  GF  treatment  inhibited  most  of  the 
thapsigargin-induced ERK phosphorylation. This indicates that for ERK phosphorylation, increased 
Ca2+ levels signal mainly by PKC activation. The weak remaining signal might have been due to 
incomplete  PKC inhibition  or  it  might  suggest  that  there  is  indeed  signaling  through  another 
pathway.  Pretreatment with EGFR inhibitors gefitinib and cetuximab did not affect NT-induced 
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ERK phosphorylation significantly, as could be expected. 
Phosphorylation of Akt
The  average  Akt  phosphorylation  increased  slightly  in  response  to  PKC  inhibition  in  our 
experiments. This response was very small compared to the EGF-induced Akt phosphorylation, but 
increased the basal Akt phosphorylation from about 40 % to about 70 % of max NT-induced effect. 
This observation may be explained by reduced inhibitory feedback from PKC on EGFR or some 
other RTK [14]. It may also be caused by contamination from neighboring wells containing large 
amounts  of  pAkt.  Such  an  explanation  would  be  likely  if  this  was  only  observed  in  EGF 
experiments,  but  it  seemed  to  be  present  in  the  experiments  with  NT as  well,  rendering  this 
hypothesis  less  likely.  Regardless  of the cause,  the uncertainties  are  too large for anything but 
speculation.  The effect of Akt phosphorylation in response to inhibition of PKC by GF was small 
and uncertain for NT and EGF stimulation respectively. Gefitinib and cetuximab inhibited EGF- 
induced Akt activation as could be expected and cetuximab had no convincing effect upon NT 
stimulated  Akt  activation.  However,  the  fact  that  gefitinib  seemed  to  inhibit  NT-induced  Akt 
phosporylation was unexpected. This could suggest that the EGF receptor is involved in mediating 
the  NT-induced  Akt  phosphorylation  for  instance  by  transactivation,  although  we  found  no 
phosphorylation of the EGF receptor on pY1173. However this might as well be a nonspecific effect 
of  the  large  concentration  of  gefitinib  we  used,  which  also  affected  (increased)  ERK 
phosphorylation at 10 μM. It is noteworthy that Akt was not activated in the experiments with TPA 
and thapsigargin , thus indicating that Akt activation is initiated upstream of calcium release and 
PKC activation. In the case of EGF stimulation this can be explained by EGFRs activating PI3K, 
but  for  NT stimulation  there  is  no well  established link  between GPCRs and PI3K activation, 
although  it has  recently  been  demonstrated  that  neurotensin-stimulated  Akt  phosphorylation  is 
abolished by pretreating the cells with TGX-221, an inhibitor of PI3Kβ [34]. 
Phosphorylation of EGFR
As previously mentioned we were only able to observe EGFR phosphorylation in our experiments 
with  EGF.  We observed no apparent  NT-induced transactivation  upon treatment  with  the  PKC 
inhibitor GF. The EGFR receptor was not phosphorylated after treatment with TPA or thapsigargin, 
but if  our method was sensitive enough we might  have expected to  see some reduction in  the 
reported basal EGFR phosphorylation when activating PKC using TPA [17]. 
CONCLUSIONS
We have found evidence indicating that EGF-induced ERK activation is mediated equally through a 
Ca2+/PKC-dependent pathway, and a non PKC-dependent pathway. We may speculate that these 
pathways are parts of the  PLC-γ/DAG+IP3/Ca2+/PKC/ERK- and the Ras/Raf/Mek/ERK-cascades 
respectively.  For NT-induced ERK activation our evidence suggests a  PKC dependent  pathway 
only.  Activation of Akt is initiated upstream of increased intracellular calcium and activation of 
PKC.
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Note:  these  pictures  are  compressed  pictures  of  the  blots  used  for  quantitation,  and data  may  
therefore have been lost.
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